Borneol

Research use only, not for human use.

Extracted from Cinnamomum cassia. It is a TRPM9 agonist that increases ocular surface wetness.

Extracted from Cinnamomum cassia. It is a TRPM9 agonist that increases ocular surface wetness.

DL-Borneol increases intracellular accumulation of Rho123, and enhances P-gp substrates across the BBB in vitro, and also depresses mdr1a mRNA and P-gp expression. Furthermore, DL-Borneol could activate NF-κB and inhibition of NF-κB with MG132 and SN50 obscures the P-gp decreases induced by DL-Borneol. 10 μg/mL and 20 μg/mL DL-Borneol significantly increase phosphorylation of IκB expression at 30 min after treatment transiently. DL-Borneol treatment decreases P-gp expression in BMECs.

DL-Borneol significantly suppresses the process of epileptogenesis in PTZ-kindled mice. The biochemical alterations induced by PTZ kindling are ameliorated in DL-Borneol-treated animals which is indicated by decreased LPO and increased SOD, GSH, CAT levels. The distinct neuronal damage observed in the kindled group is counteracted by DL-Borneol. Furthermore, it decreases the levels of GFAP which is manifested by reduced immunostaining. The pathological damages of ischemia-reperfusion have a significant impact on the pharmacokinetic traits of DL-Borneol and that there are some components in Xingnaojing inhibiting the absorption of DL-Borneol.

(±)-Borneol | DL-Borneol

Metabolic Enzyme/Protease

CYPs

CYP2D|TRPM8

Metabolic Disease

Stroke

507-70-0

154.24

C10H18O

>98% (HPLC)

DMSO:10 mM

CC1(C)[C@H]2CC[C@]1(C)[C@H](O)C2.CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](O)C2

Bicyclo(2.2.1)heptan-2-ol 177-trimethyl- (1R2S4R)-rel-

(-20℃)

With Ice Pack

≥ 2 years